Clinomics Balance Sheet Health
Financial Health criteria checks 4/6
Clinomics has a total shareholder equity of ₩42.9B and total debt of ₩17.8B, which brings its debt-to-equity ratio to 41.4%. Its total assets and total liabilities are ₩74.5B and ₩31.6B respectively.
Key information
41.4%
Debt to equity ratio
₩17.77b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩13.15b |
| Equity | ₩42.91b |
| Total liabilities | ₩31.58b |
| Total assets | ₩74.48b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: A352770's short term assets (₩18.2B) do not cover its short term liabilities (₩20.4B).
Long Term Liabilities: A352770's short term assets (₩18.2B) exceed its long term liabilities (₩11.2B).
Debt to Equity History and Analysis
Debt Level: A352770's net debt to equity ratio (10.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if A352770's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A352770 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A352770 is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.